Actualités

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]

Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...

FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...

Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 […]

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.

Drug companies have found promising new options for one of the most aggressive and hardest-to-treat forms of breast cancer after decades with few breakthroughs. Gilead Sciences won Food and Drug Administration approval Wednesday to sell its drug Trodelvy as a first treatment for newly diagnosed patients with the advanced form of a type of breast cancer known as “triple negative” because it has characteristics that render common treatments ineffective. It is the second such approval in about a month: AstraZeneca and Daiichi Sankyo rival drug, Datroway, was approved for a similar group of patients in May.

By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.

By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, […] The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.

With a short percentage of shares outstanding of 2.07%, Gilead Sciences, Inc. (NASDAQ:GILD) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for Yeztugo 300-mg tablets as a potential once-weekly oral pre-exposure prophylaxis (PrEP) treatment for HIV prevention. […]

Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE in children and adolescents at higher risk for pneumococcal disease, making it the only PCV indicated for this US group. Merck and Gilead reported positive Phase 3 data for a once weekly oral HIV treatment regimen. Separately, Merck discontinued a Phase 3 lung cancer trial...

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short of the S&P 500’s 10.9% gain during that period.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus […]

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

Gilead Sciences (GILD) reached $124.3 at the closing of the latest trading day, reflecting a -1.03% change compared to its last close.

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Top 10 Income Stocks with the Highest Upside Potential. On May 22, Reuters reported that Gilead Sciences, Inc. (NASDAQ:GILD) said its experimental drug for a rare and potentially fatal liver infection had received US approval. The U.S. Food and Drug Administration approved Hepcludex for the treatment of […]

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis (PBC), supporting alkaline phosphatase (ALP) normalization as a treatment goal. The US Food and Drug Administration granted accelerated approval for Livdelzi in PBC. The FDA also approved Hepcludex for the treatment of hepatitis delta virus infection. Gilead Sciences, known for its focus on antiviral and liver disease treatments, is adding fresh momentum to its liver...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to invest in. On June 2, Gilead Sciences announced positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in patients with primary biliary cholangitis/PBC. The study showed statistically significant improvements in composite alkaline phosphatase/ALP normalization compared with placebo after 52 weeks. The trial […]

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 7 Best Longevity Stocks to Buy Now. On June 5, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) applauded the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. CEO Daniel O’Day said South Africa is “at the heart of global […]

Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy […]

Gilead Sciences, Inc. (NASDAQ:GILD) is a deep value stock to invest in now. On June 2, Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results of the Phase 3 IDEAL study for its candidate drug Livdelzi in people with primary biliary cholangitis (PBC). Study results showed that treatment with Livdelzi (seladelpar) led to significantly more patients achieving […]